Man Group plc bought a new position in HealthEquity, Inc. (NASDAQ:HQY – Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 67,560 shares of the company’s stock, valued at approximately $6,102,000. Man Group plc owned about 0.08% of HealthEquity as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. BlackRock Inc. acquired a new stake in shares of HealthEquity during the 2nd quarter valued at about $1,018,621,000. William Blair Investment Management LLC acquired a new position in HealthEquity in the 4th quarter worth about $169,956,000. Jupiter Topco LLC acquired a new position in HealthEquity in the 2nd quarter worth about $78,847,000. Wasatch Advisors LP boosted its position in HealthEquity by 10.5% during the second quarter. Wasatch Advisors LP now owns 7,960,735 shares of the company’s stock worth $719,014,000 after purchasing an additional 757,801 shares in the last quarter. Finally, Norges Bank purchased a new position in HealthEquity during the fourth quarter worth approximately $66,927,000. 99.55% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
A number of research firms recently issued reports on HQY. Royal Bank Of Canada lifted their price target on shares of HealthEquity from $100.00 to $108.00 and gave the company an “outperform” rating in a research note on Wednesday, June 3rd. Barrington Research restated an “outperform” rating and set a $110.00 price objective on shares of HealthEquity in a research report on Friday, May 22nd. Wall Street Zen raised shares of HealthEquity from a “hold” rating to a “buy” rating in a report on Saturday, August 22nd. Citigroup reiterated a “market outperform” rating on shares of HealthEquity in a research report on Friday. Finally, Weiss Ratings raised shares of HealthEquity from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, June 5th. Eleven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $110.93.
More HealthEquity News
Here are the key news stories impacting HealthEquity this week:
- Positive Sentiment: HealthEquity exceeded expectations with adjusted earnings of $1.24 per share versus the $1.19 consensus, while revenue reached $350.7 million, slightly above estimates. Revenue increased 95.5% year over year. HealthEquity Q2 Earnings and Revenues Top Estimates
- Positive Sentiment: Profitability improved, with net income rising 10% to $65.6 million and net margin expanding to 19% from 18%. Adjusted EBITDA grew 11% to $167 million, while its margin increased to 48% from 46%. HealthEquity Second-Quarter Financial Results
- Positive Sentiment: Management raised fiscal 2027 adjusted EPS guidance to $4.66–$4.73, above the $4.56 analyst consensus. Record HSA assets of $37.9 billion provide additional support for the company’s long-term growth outlook. HealthEquity Raises Fiscal 2027 Guidance
- Positive Sentiment: BTIG Research reaffirmed its “buy” rating and raised its price target to $115. Another analysis indicated that HQY could be approximately 19% undervalued after the guidance increase, reinforcing the bullish interpretation of the earnings update. BTIG Research Rating HealthEquity Could Be Undervalued
- Neutral Sentiment: Fiscal 2027 revenue guidance of approximately $1.4 billion was broadly in line with expectations, so the guidance improvement was driven mainly by stronger anticipated earnings and margins.
- Negative Sentiment: Director Adrian T. Dillon sold 7,632 shares valued at approximately $798,000, reducing his position by 10.9%. The sale was executed under a pre-arranged Rule 10b5-1 plan, which reduces its negative signaling value but could still attract investor attention. HealthEquity Director Stock Sale
- Negative Sentiment: HQY trades at a premium valuation of roughly 35 times earnings. After the recent advance toward its 52-week high, some investors may lock in gains, potentially tempering the stock’s reaction to otherwise favorable fundamentals.
Insider Buying and Selling
In other HealthEquity news, EVP Michael Henry Fiore sold 2,354 shares of the business’s stock in a transaction dated Friday, July 10th. The shares were sold at an average price of $95.00, for a total transaction of $223,630.00. Following the sale, the executive vice president directly owned 52,244 shares in the company, valued at $4,963,180. This represents a 4.31% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Adrian T. Dillon sold 7,632 shares of the company’s stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $104.61, for a total transaction of $798,383.52. Following the sale, the director directly owned 62,395 shares in the company, valued at approximately $6,527,140.95. The trade was a 10.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 12,456 shares of company stock worth $1,256,664 over the last three months. Insiders own 1.60% of the company’s stock.
HealthEquity Stock Performance
Shares of HealthEquity stock opened at $96.37 on Friday. The business’s 50 day moving average price is $98.16 and its 200 day moving average price is $87.87. The company has a market cap of $8.06 billion, a price-to-earnings ratio of 34.79, a PEG ratio of 1.62 and a beta of 0.21. The company has a debt-to-equity ratio of 0.47, a quick ratio of 3.44 and a current ratio of 2.99. HealthEquity, Inc. has a one year low of $72.76 and a one year high of $107.62.
HealthEquity (NASDAQ:HQY – Get Free Report) last announced its quarterly earnings data on Thursday, August 27th. The company reported $1.24 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.19 by $0.05. The firm had revenue of $350.73 million during the quarter, compared to analyst estimates of $349.22 million. HealthEquity had a net margin of 17.36% and a return on equity of 15.33%. The company’s quarterly revenue was up 95.5% compared to the same quarter last year. HealthEquity has set its FY 2027 guidance at 4.660-4.730 EPS. On average, research analysts predict that HealthEquity, Inc. will post 3.92 EPS for the current year.
HealthEquity Company Profile
HealthEquity, Inc (NASDAQ: HQY) is a leading administrator of consumer-directed health accounts and related benefit solutions in the United States. Founded in 2002 and headquartered in Draper, Utah, the company specializes in health savings accounts (HSAs) and offers complementary services such as flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), COBRA administration and commuter benefits. Through its technology-driven platform, HealthEquity enables employers, health plans and individuals to streamline account management, improve cost transparency and encourage more informed healthcare spending.
Serving millions of members across all 50 states, HealthEquity leverages an open-architecture ecosystem that integrates with health plans, payroll providers and financial institutions.
Featured Articles
- Five stocks we like better than HealthEquity
- From SaaS-pocalypse to Perfect Storm: Workday’s AI Growth Story Strengthens
- These 3 GARP Stocks Show Why Growth and Value Do Not Have to Clash
- Venture Into High-Volatility Corners of the Market With These 3 ETFs
- 3 Retail Stocks to Watch After a Big Consumer Earnings Week
Receive News & Ratings for HealthEquity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HealthEquity and related companies with MarketBeat.com's FREE daily email newsletter.
